BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
48
Specified Dose on Specified Days
Specified Dose on Specified Days
PRA Health Sciences - Lenexa
Lenexa, Kansas, United States
Maximum observed plasma concentration (Cmax) of BMS-986165 with and without UGT1A9 inhibitor
Time frame: Up to 14 days
Area under the plasma concentration-time AUC (0-T) of BMS-986165 with and without UGT1A9 inhibitor
Time frame: up to 14 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time AUC(INF) for BMS-986165 with and without UGT1A9 inhibitor
Time frame: up to 14 days
Incidence of Adverse Events (AEs)
Time frame: up to 48 days
Number of participants with 12-lead Electrocardiogram (ECG) Abnormalities
Time frame: up to 48 days
Physical Examination of weight
Time frame: up to 48 days
Number of changes in blood pressure
Time frame: up to 20 days
Number of changes in body temperature
Time frame: up to 20 days
Number of changes in respiratory rate
Time frame: up to 20 days
Number of clinical significant changes in lab assessment of blood serum
Time frame: up to 48 days
Number of Clinically significant changes in assessment of blood
Time frame: up to 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Clinically significant changes in lab assessment of urine
Time frame: up to 20 days